Vietnam Pulmonary Arterial Hypertension Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Pulmonary Arterial Hypertension Drugs market is growing globally due to the increasing rates of respiratory and cardiovascular diseases, as well as an ageing population. A change in lifestyle, such as excessive alcohol use, a lack of exercise, and unhealthy eating habits, has increased the risk of hypertension and high blood pressure, increasing prevalence of PAH, advancements in drug therapies, advancements in research and development, growing patient awareness leading to early diagnosis and treatment initiation, support from regulatory authorities, increasing healthcare expenditure and collaborations between pharmaceutical companies. GlaxoSmithKline PLC., Teva Pharmaceuticals Industries Ltd., Actelion Pharmaceuticals US, Inc., United Therapeutics Corp., Sandoz AG, Dr. Reddy's Laboratories Ltd, Par Pharmaceutical., Natco Pharma Ltd., Zydus Pharmaceutical USA., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Mylan N.V., Sigmapharm Laboratories, LLC., Gilead Sciences, Inc., Pfizer Inc., Amneal Pharmaceutical Inc. are the key global market players in pulmonary arterial hypertension drugs market.
Vietnam Pulmonary Arterial Hypertension Drugs Market is valued at around $37.2 Mn in 2022 and is projected to reach $55.8 Mn by 2030, exhibiting a CAGR of 5.19% during the forecast period 2023-2030.
A rare condition that affects the pulmonary arteries is known as pulmonary arterial hypertension (PAH). Pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) are terms for high blood pressure in the lungs. It is characterized by capillaries and arteries that are clogged and constricted. If this rare disease is not treated, it will typically get worse over time and may even be fatal. Although there is no known treatment for PAH, there are several ways to control the disease's symptoms, halt its progression, and enhance quality of life. Pharmacological therapy includes prostacyclin analogs such as epoprostenol, treprostinil, and iloprost mimic the effects of prostacyclin, a natural vasodilator, and help relax and widen blood vessels in the lungs. Endothelin Receptor Antagonists (ERAs) which include medications like bosentan, ambrisentan, and macitentan block the action of endothelin, a substance that causes blood vessels to constrict. Phosphodiesterase-5 (PDE-5) Inhibitors which include drugs such as sildenafil and tadalafil inhibit the breakdown of cyclic guanosine monophosphate (cGMP), a compound that promotes vasodilation. Soluble Guanylate Cyclase (sGC) Stimulator drugs like riociguat stimulate the production of cGMP leading to vasodilation, and calcium channel blockers like amlodipine.
Supportive Therapy which includes oxygen therapy, physical activity like regular exercise, tailored to an individual's capacity, and surgical procedures like lung transplantation can also be performed. GlaxoSmithKline PLC., Teva Pharmaceuticals Industries Ltd., Actelion Pharmaceuticals US, Inc., United Therapeutics Corp., Sandoz AG, Dr. Reddy's Laboratories Ltd, Par Pharmaceutical., Natco Pharma Ltd., Zydus Pharmaceutical USA., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Mylan N.V., Sigmapharm Laboratories, LLC., Gilead Sciences, Inc., Pfizer Inc., Amneal Pharmaceutical Inc. are the key global market players in pulmonary arterial hypertension drugs market.
Market Growth Drivers
Increasing rates of respiratory and cardiovascular diseases, as well as an aging population. A change in lifestyle, such as excessive alcohol use, a lack of exercise, and unhealthy eating habits, has increased the risk of hypertension and high blood pressure, increasing prevalence of PAH, advancements in drug therapies, advancements in research and development, growing patient awareness leading to early diagnosis and treatment initiation, support from regulatory authorities, increasing healthcare expenditure and collaborations between pharmaceutical companies. All these factors act as market growth drivers.
Market Restraints
High Cost of Treatment, Limited Awareness, and Underdiagnosis, Adverse Side Effects associated with treatment which lead to treatment discontinuation by patients, and limited treatment options. All these factors act as market growth restraints.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Type
By Route of Administration
By Distribution Channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.